HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by LIEBERMAN, A. Articles by GOLDSTEIN, M. Search for Related Content PubMed PubMed Citation Articles by LIEBERMAN, A. Articles by GOLDSTEIN, M.

Studies on the antiparkinsonian efficacy of lergotrile

Departments of Neurology, Neurosurgery, and Psychiatry, Neurochemistry Laboratories, New York University Medical Center, New York City.

The antiparkinsonian activity of lergotrile mesylate, a presumed dopaminergic receptor stimulating agent, was investigated in monkeys with surgically induced tremor and in parkinsonian patients. The administration of lergotrile resulted in a dose-dependent reduction in the intensity of tremor in the monkeys. In 13 patients with Parkinson's disease treated with lergotrile (up to 12 mg a day), overall improvement was observed in five. Tremor was the main clinical feature to benefit, and the improvement reached statistical significance. In a subgroup of four patients treated with a higher dose of lergotrile (up to 20 mg a day), further improvement in rigidity and bradykinesia was noted, but again, only improvement in tremor was statistically significant. Adverse effects included orthostatic hypotension, behavioral alterations, and nausea and vomiting. These were severe enough to result in drug withdrawal in three patients.

This work was supported by USPHS grant NS-06801 and NSF grant GB 27603.

Received for publication November 1, 1974.

Dr. Goldstein's address is Department of Psychiatry, Neurochemistry Laboratories, New York University Medical Center, 550 First Avenue, New York, NY 10016.

This article has been cited by other articles:

				L Lemberger and R. Crabtree Pharmacologic effects in man of a potent, long-acting dopamine receptor agonist Science, September 14, 1979; 205(4411): 1151 - 1153. [Abstract] [PDF]

				W. J. Weiner, J. Kramer, P. A. Nausieda, and H. L. Klawans Paradoxical Response to Dopaminergic Agents in Parkinsonism Arch Neurol, July 1, 1978; 35(7): 453 - 455. [Abstract] [PDF]

				A. Lieberman, E. Estey, M. Kupersmith, G. Gopinathan, and M. Goldstein Treatment of Parkinson's Disease With Lergotrile Mesylate JAMA, November 28, 1977; 238(22): 2380 - 2382. [Abstract] [PDF]